Hormones and calcium metabolism

Research output: Contribution to journalArticle

Abstract

This study shows that lack of estrogens plays a decisive role in the development of postmenopausal bone loss. It seems that one of the physiological changes after the menopause is that bone, in the absence of estrogens, becomes more sensitive to the action of parathyroid hormone. Thus oophorectomy is accompanied by a rise in plasma and urine calcium and urine hydroxyproline due to increased bone resorption, and this imbalance between parathyroid hormone and bone is restored by the administration of estrogens which return the biochemical abnormalities towards the normal premenopausal state. Retrospective studies on patients who have received estrogen therapy have shown that treated patients maintain their bone status better than controls. As there are no long term studies of bone density on patients taking progestational compounds it is as yet uncertain how important their role may be. However, since their biochemical effects on calcium metabolism are very similar to those of estrogens they may also help to preserve bone status. The data provide a rational basis for the prevention of postmenopausal bone loss. Both estrogen and progesterone appear to block bone resorption, and when given together it may be possible to use smaller doses of both hormones to achieve the same effect that each produces when given separately in larger doses. This type of 'combined preparation' may be more acceptable physiologically than either hormone alone. This paper has not dealt with calcium therapy. The authors have reason to believe that estrogen deficiency has the effect of increasing the calcium requirement in the postmenopausal women. An alternative approach to the prevention of osteoporosis would be to increase the calcium intake, and data published elsewhere show that this too can be effective. The ultimate therapy may be the combination of hormones with calcium supplements, but long term results of such therapy are not yet available.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalORGANORAMA
Volume10
Issue number4
StatePublished - 1973
Externally publishedYes

Fingerprint

Estrogens
Hormones
Calcium
Bone and Bones
Postmenopausal Osteoporosis
Bone Resorption
Parathyroid Hormone
Urine
Hydroxyproline
Ovariectomy
Progestins
Therapeutics
Menopause
Bone Density
Osteoporosis
Progesterone
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Gallagher, J. C. G., & Nordin, B. E. C. (1973). Hormones and calcium metabolism. ORGANORAMA, 10(4), 3-10.

Hormones and calcium metabolism. / Gallagher, John Christopher G.; Nordin, B. E C.

In: ORGANORAMA, Vol. 10, No. 4, 1973, p. 3-10.

Research output: Contribution to journalArticle

Gallagher, JCG & Nordin, BEC 1973, 'Hormones and calcium metabolism', ORGANORAMA, vol. 10, no. 4, pp. 3-10.
Gallagher, John Christopher G. ; Nordin, B. E C. / Hormones and calcium metabolism. In: ORGANORAMA. 1973 ; Vol. 10, No. 4. pp. 3-10.
@article{de2da3faefd24cd998e67dbabf029ac4,
title = "Hormones and calcium metabolism",
abstract = "This study shows that lack of estrogens plays a decisive role in the development of postmenopausal bone loss. It seems that one of the physiological changes after the menopause is that bone, in the absence of estrogens, becomes more sensitive to the action of parathyroid hormone. Thus oophorectomy is accompanied by a rise in plasma and urine calcium and urine hydroxyproline due to increased bone resorption, and this imbalance between parathyroid hormone and bone is restored by the administration of estrogens which return the biochemical abnormalities towards the normal premenopausal state. Retrospective studies on patients who have received estrogen therapy have shown that treated patients maintain their bone status better than controls. As there are no long term studies of bone density on patients taking progestational compounds it is as yet uncertain how important their role may be. However, since their biochemical effects on calcium metabolism are very similar to those of estrogens they may also help to preserve bone status. The data provide a rational basis for the prevention of postmenopausal bone loss. Both estrogen and progesterone appear to block bone resorption, and when given together it may be possible to use smaller doses of both hormones to achieve the same effect that each produces when given separately in larger doses. This type of 'combined preparation' may be more acceptable physiologically than either hormone alone. This paper has not dealt with calcium therapy. The authors have reason to believe that estrogen deficiency has the effect of increasing the calcium requirement in the postmenopausal women. An alternative approach to the prevention of osteoporosis would be to increase the calcium intake, and data published elsewhere show that this too can be effective. The ultimate therapy may be the combination of hormones with calcium supplements, but long term results of such therapy are not yet available.",
author = "Gallagher, {John Christopher G.} and Nordin, {B. E C}",
year = "1973",
language = "English",
volume = "10",
pages = "3--10",
journal = "ORGANORAMA",
issn = "0369-7762",
number = "4",

}

TY - JOUR

T1 - Hormones and calcium metabolism

AU - Gallagher, John Christopher G.

AU - Nordin, B. E C

PY - 1973

Y1 - 1973

N2 - This study shows that lack of estrogens plays a decisive role in the development of postmenopausal bone loss. It seems that one of the physiological changes after the menopause is that bone, in the absence of estrogens, becomes more sensitive to the action of parathyroid hormone. Thus oophorectomy is accompanied by a rise in plasma and urine calcium and urine hydroxyproline due to increased bone resorption, and this imbalance between parathyroid hormone and bone is restored by the administration of estrogens which return the biochemical abnormalities towards the normal premenopausal state. Retrospective studies on patients who have received estrogen therapy have shown that treated patients maintain their bone status better than controls. As there are no long term studies of bone density on patients taking progestational compounds it is as yet uncertain how important their role may be. However, since their biochemical effects on calcium metabolism are very similar to those of estrogens they may also help to preserve bone status. The data provide a rational basis for the prevention of postmenopausal bone loss. Both estrogen and progesterone appear to block bone resorption, and when given together it may be possible to use smaller doses of both hormones to achieve the same effect that each produces when given separately in larger doses. This type of 'combined preparation' may be more acceptable physiologically than either hormone alone. This paper has not dealt with calcium therapy. The authors have reason to believe that estrogen deficiency has the effect of increasing the calcium requirement in the postmenopausal women. An alternative approach to the prevention of osteoporosis would be to increase the calcium intake, and data published elsewhere show that this too can be effective. The ultimate therapy may be the combination of hormones with calcium supplements, but long term results of such therapy are not yet available.

AB - This study shows that lack of estrogens plays a decisive role in the development of postmenopausal bone loss. It seems that one of the physiological changes after the menopause is that bone, in the absence of estrogens, becomes more sensitive to the action of parathyroid hormone. Thus oophorectomy is accompanied by a rise in plasma and urine calcium and urine hydroxyproline due to increased bone resorption, and this imbalance between parathyroid hormone and bone is restored by the administration of estrogens which return the biochemical abnormalities towards the normal premenopausal state. Retrospective studies on patients who have received estrogen therapy have shown that treated patients maintain their bone status better than controls. As there are no long term studies of bone density on patients taking progestational compounds it is as yet uncertain how important their role may be. However, since their biochemical effects on calcium metabolism are very similar to those of estrogens they may also help to preserve bone status. The data provide a rational basis for the prevention of postmenopausal bone loss. Both estrogen and progesterone appear to block bone resorption, and when given together it may be possible to use smaller doses of both hormones to achieve the same effect that each produces when given separately in larger doses. This type of 'combined preparation' may be more acceptable physiologically than either hormone alone. This paper has not dealt with calcium therapy. The authors have reason to believe that estrogen deficiency has the effect of increasing the calcium requirement in the postmenopausal women. An alternative approach to the prevention of osteoporosis would be to increase the calcium intake, and data published elsewhere show that this too can be effective. The ultimate therapy may be the combination of hormones with calcium supplements, but long term results of such therapy are not yet available.

UR - http://www.scopus.com/inward/record.url?scp=0015713369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015713369&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0015713369

VL - 10

SP - 3

EP - 10

JO - ORGANORAMA

JF - ORGANORAMA

SN - 0369-7762

IS - 4

ER -